New funding for Xeltis, creating restorative cardiovascular implants
Xeltis, a clinical-stage medtech company developing living implants that enable the body to restore cardiovascular function, has raised €32 million in a Series D2 equity fundraise. The fundraising has been backed by a syndicate of current and new investors, including…